468 Metastatic renal cell carcinoma (MRCC): Responses to different immunotherapies

Aim to compare clinical responses and survival (median overall survival -MOS- and 2 year survival -% S-) in 48 patients treated with different immunotherapies for MRCC (Interferon -IFN- and Interleukin-2-IL-2-). Methods the patients were treated in the following ways: — 18 with IFN—(9 MU s.c. 3 times/week × 6 months): group A; — 11 with IL-2 (18 MU/m2 i.v. × 4 days/months c.i.): group B; — 19 with IFN + IL-2 (at the same dosages): group C. Responses were evaluated as complete response (CR), partial response (PR), stable disease (SD), progression (PD), not evaluable (NE). Results 1 CR, 1 PR and 5 SD were seen in the group A (MOS = 15 months; %S = 32); OCR, 3 PR and 2SD in the group B (MOS = 16 months; % S = 36); 1 CR, 4 PR and 4 SD in the group C (MOS = 18 months; % S = 44). Total: 2 CR, 8 PR, 11 SD, 21 PD, 6 NE (MOS = 17 months; % S = 38). 21 patients died; 21 are still alive. Conclusions (1) we observed 43% of responses (CR + PR + SD) in all patients; (2) a higher (but not significant) rate of CR + PR was observed in the groups treated with IL-2 including regimens (27 and 26% vs 11%) (3) survival was in accordance with these observations.